SCHEMBL6496889

SCHEMBL6496889

CCCOc1ccc(Nc2ncnc(Cl)n2)cc1OCCC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHB4 P54760 1/20 0.49
MAPT P10636 5/20 0.46
HSD17B10 Q99714 1/20 0.46
KDM4E B2RXH2 2/20 0.42
NFKB1 P19838 1/20 0.42
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
KMT2A Q03164 1/20 0.41
IGF1R P08069 1/20 0.41
EGFR P00533 3/20 0.40
MAPK1 P28482 1/20 0.39
ENPP1 P22413 1/20 0.39
GAA P10253 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
KDR P35968 3/20 0.38
JAK2 O60674 1/20 0.38
PTK2 Q05397 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
ADORA3 P0DMS8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6481885 0.89 EPHB4 (0.51) EPHB4MAPTKDM4ENFKB1MEN1
SCHEMBL6481335 0.84 EPHB4 (0.55) EPHB4MAPTMEN1LMNAKMT2A
SCHEMBL6495796 0.84 EPHB4 (0.55) EPHB4MAPTMEN1LMNAKMT2A
SCHEMBL4941396 0.81 EPHB4 (0.64) EPHB4MAPTMEN1LMNAKMT2A
SCHEMBL6483193 0.75 KDR (0.57) EPHB4MAPTEGFRKDRADORA3
SCHEMBL7041792 0.73 MAPT (0.44) MAPTHSD17B10MEN1LMNAKMT2A
SCHEMBL13612601 0.73 MAPT (0.44) MAPTHSD17B10MEN1LMNAKMT2A
SCHEMBL7046869 0.73 MAPT (0.44) MAPTHSD17B10MEN1LMNAKMT2A
SCHEMBL7045169 0.73 MAPT (0.44) MAPTHSD17B10MEN1LMNAKMT2A
SCHEMBL17631140 0.71 EPHB4 (0.52) EPHB4IGF1RKDRPTK2AURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6881737-B2 Substituted triazinyl acrylamide derivatives and methods of use AMGEN INC. (US) 2005-04-19 US disclosed
US-20030139416-A1 Substituted triazinyl acrylamide derivatives and methods of use AMGEN INC. 2003-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139416-A1 Substituted triazinyl acrylamide derivatives and methods of use PKD1, PKD2, GLS EPHB4 3547/4885MAPT 4216/4885HSD17B10 2007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.